Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities

Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory S. Young, Omar Elnaggar, Zheng Che, Cynthia D. Timmers, Priyani Rajasekera, Jennifer M. Maskarinec, Mark Bloomston, Tanios Bekaii-Saab, Denis C. Guttridge, Gregory B. Lesinski

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Involuntary weight loss, a part of the cachexia syndrome, is a debilitating comorbidity of cancer and currently has no treatment options. Results from a recent clinical trial at our institution showed that biliary tract cancer patients treated with a MEK inhibitor exhibited poor tumor responses but surprisingly gained weight and increased their skeletal muscle mass. This implied that MEKinhibition might be anticachectic. To test this potential effect of MEK inhibition, we utilized the established Colon-26 model of cancer cachexia and the MEK1/2 inhibitor MEK162. Results showed that MEK inhibition effectively prevented muscle wasting. Importantly, MEK162 retained its ability to spare muscle loss even in mice bearing a Colon-26 clone resistant to the MEK inhibitor, demonstrating that the effects of blocking MEK are at least in part independent of the tumor. Because single-agent MEK inhibitors have been limited as a first-line targeted therapy due to compensatory activation of other oncogenic signaling pathways, we combined MEK162 with the PI3K/Akt inhibitor buparlisib. Results showed that this combinatorial treatment significantly reduced tumor growth due to a direct activity on Colon-26 tumor cells in vitro and in vivo, while also preserving skeletal muscle mass. Together, our results suggest that as a monotherapy, MEK inhibition preserves muscle mass, but when combined with a PI3K/ Akt inhibitor exhibits potent antitumor activity. Thus, combinatorial therapy might serve as a new approach for the treatment of cancer cachexia.

Original languageEnglish (US)
Pages (from-to)344-356
Number of pages13
JournalMolecular cancer therapeutics
Volume16
Issue number2
DOIs
StatePublished - Feb 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities'. Together they form a unique fingerprint.

  • Cite this

    Talbert, E. E., Yang, J., Mace, T. A., Farren, M. R., Farris, A. B., Young, G. S., Elnaggar, O., Che, Z., Timmers, C. D., Rajasekera, P., Maskarinec, J. M., Bloomston, M., Bekaii-Saab, T., Guttridge, D. C., & Lesinski, G. B. (2017). Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor-extrinsic and -intrinsic activities. Molecular cancer therapeutics, 16(2), 344-356. https://doi.org/10.1158/1535-7163.MCT-16-0337